ZA9896B - Vitronectin receptor antagonists - Google Patents

Vitronectin receptor antagonists

Info

Publication number
ZA9896B
ZA9896B ZA9896A ZA9896A ZA9896B ZA 9896 B ZA9896 B ZA 9896B ZA 9896 A ZA9896 A ZA 9896A ZA 9896 A ZA9896 A ZA 9896A ZA 9896 B ZA9896 B ZA 9896B
Authority
ZA
South Africa
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Application number
ZA9896A
Other languages
English (en)
Inventor
William H Miller
William E Bondinell
Thomas Wen Fu Ku
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA9896B publication Critical patent/ZA9896B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
ZA9896A 1997-01-08 1998-01-07 Vitronectin receptor antagonists ZA9896B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3402697P 1997-01-08 1997-01-08

Publications (1)

Publication Number Publication Date
ZA9896B true ZA9896B (en) 1998-10-14

Family

ID=21873846

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9896A ZA9896B (en) 1997-01-08 1998-01-07 Vitronectin receptor antagonists

Country Status (30)

Country Link
US (2) US6069158A (de)
EP (1) EP0977735B1 (de)
JP (1) JP2001508067A (de)
KR (1) KR20000069941A (de)
CN (1) CN1249745A (de)
AP (1) AP9901597A0 (de)
AR (1) AR010873A1 (de)
AT (1) ATE235467T1 (de)
AU (1) AU729641B2 (de)
BG (1) BG103548A (de)
BR (1) BR9806852A (de)
CA (1) CA2276738A1 (de)
CO (1) CO4920232A1 (de)
DE (1) DE69812602T2 (de)
DZ (1) DZ2395A1 (de)
EA (1) EA199900630A1 (de)
ES (1) ES2196534T3 (de)
HU (1) HUP0001945A3 (de)
ID (1) ID23168A (de)
IL (1) IL130760A0 (de)
MA (1) MA26462A1 (de)
NO (1) NO993350L (de)
NZ (1) NZ336560A (de)
OA (1) OA11076A (de)
PE (1) PE44799A1 (de)
PL (1) PL334499A1 (de)
SK (1) SK92799A3 (de)
TR (1) TR199901575T2 (de)
WO (1) WO1998030542A1 (de)
ZA (1) ZA9896B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011626A1 (en) * 1997-09-04 1999-03-11 Smithkline Beecham Corporation Integrin receptor antagonists
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
PE122699A1 (es) * 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
WO1999052872A1 (en) 1998-04-09 1999-10-21 Meiji Seika Kaisha, Ltd. AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS
JP4240424B2 (ja) * 1998-10-23 2009-03-18 エルジー ディスプレイ カンパニー リミテッド エッチング剤及びこれを用いた電子機器用基板の製造方法
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
EP1150965A4 (de) 1999-02-03 2002-05-15 Merck & Co Inc Benzazepin derivate als alpha-v intgrin rezeptor antagonisten
DE19916837A1 (de) * 1999-04-14 2000-10-19 Merck Patent Gmbh Dibenzoazulenderivate
EP1209152A4 (de) 1999-08-05 2003-03-12 Meiji Seika Kaisha Omega-amino-alpha-hydroxy-carbonsäure-derivate mit einem integrin alpha v beta antagonismus
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2004513953A (ja) 2000-10-24 2004-05-13 メルク エンド カムパニー インコーポレーテッド ジベンズオキサゼピンαVインテグリン受容体アンタゴニスト
CN1247258C (zh) 2001-04-24 2006-03-29 默克专利有限公司 使用抗血管生成剂和TNFα的联合疗法
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
EP1734996B1 (de) * 2004-04-02 2013-05-22 The Regents of The University of California Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha v beta 5-integrin assoziierten krankheiten
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP1888631B1 (de) 2005-05-31 2009-09-23 Ralf Jochem Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
EA017864B1 (ru) 2007-01-18 2013-03-29 Мерк Патент Гмбх Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
CN101945853B (zh) 2007-12-21 2014-08-20 配体药物公司 选择性雄激素受体调节剂(sarm)及其应用
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
AU2010252280A1 (en) 2009-05-25 2012-01-19 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
JP5755647B2 (ja) 2009-07-24 2015-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αvβ5インテグリンに関連する疾患の処置および予防のための方法および組成物
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794424A (fr) * 1972-01-24 1973-07-23 Science Union & Cie Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament
US3906032A (en) * 1972-11-10 1975-09-16 Squibb & Sons Inc Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof
IT1222986B (it) * 1987-10-23 1990-09-12 Texcontor Ets Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
SI0910563T1 (en) * 1995-06-29 2003-10-31 Smithkline Beecham Corporation Integrin receptor antagonists
WO1997024124A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6239138B1 (en) * 1997-07-25 2001-05-29 Smithkline Beecham Corporation Vitronectin receptor antagonist
PE122699A1 (es) * 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina

Also Published As

Publication number Publication date
OA11076A (en) 2003-03-13
CO4920232A1 (es) 2000-05-29
KR20000069941A (ko) 2000-11-25
AP9901597A0 (en) 1999-09-30
EP0977735B1 (de) 2003-03-26
PL334499A1 (en) 2000-02-28
TR199901575T2 (xx) 1999-11-22
AR010873A1 (es) 2000-07-12
EP0977735A4 (de) 2000-04-05
NZ336560A (en) 2000-11-24
IL130760A0 (en) 2001-01-28
PE44799A1 (es) 1999-06-10
AU5912798A (en) 1998-08-03
BR9806852A (pt) 2001-08-07
AU729641B2 (en) 2001-02-08
CA2276738A1 (en) 1998-07-16
DZ2395A1 (fr) 2003-06-04
DE69812602D1 (de) 2003-04-30
ID23168A (id) 2000-03-23
DE69812602T2 (de) 2004-02-19
NO993350D0 (no) 1999-07-07
WO1998030542A1 (en) 1998-07-16
CN1249745A (zh) 2000-04-05
SK92799A3 (en) 1999-12-10
ATE235467T1 (de) 2003-04-15
US6191304B1 (en) 2001-02-20
EA199900630A1 (ru) 2000-02-28
MA26462A1 (fr) 2004-12-20
US6069158A (en) 2000-05-30
HUP0001945A2 (hu) 2000-10-28
ES2196534T3 (es) 2003-12-16
HUP0001945A3 (en) 2001-12-28
BG103548A (en) 2000-11-30
EP0977735A1 (de) 2000-02-09
JP2001508067A (ja) 2001-06-19
NO993350L (no) 1999-09-06

Similar Documents

Publication Publication Date Title
CY2576B1 (en) Vitronectin receptor antagonists
IL130760A0 (en) Vitronectin receptor antagonists
EP0767792A4 (de) Vitronectin-rezeptor antagonisten
ZA955391B (en) Vitronectin receptor antagonists
EP1000031A4 (de) Vitronectinrezeptor-antagonist
IL125030A0 (en) Vitronectin receptor antagonists
HUP9900754A3 (en) Vitronectin receptor antagonists
IL125034A0 (en) Vitronectin receptor antagonists
EP1007051A4 (de) Integrin rezeptor antagonisten
IL135028A0 (en) Vitronectin receptor antagonists
IL135189A0 (en) Vitronectin receptor antagonist
PL342881A1 (en) Vitronectin receptor antagonists
IL135188A0 (en) Vitronectin receptor antagonist
EP1027337A4 (de) Integrin-rezeptor-antagonisten
IL141163A0 (en) Vitronectin receptor antagonists
ZA988562B (en) Vitronectin receptor antagonists
SI0957917T1 (sl) Antagonisti receptorja vitronektina
GB9810882D0 (en) Vitronectin receptor antagonists
GB9807382D0 (en) Vitronectin receptor antagonists
GB9822331D0 (en) Vitronectin receptor antagonists
GB9812686D0 (en) Vitronectin receptor antagonists
GB9810182D0 (en) Vitronectin receptor antagonists
GB9810892D0 (en) Vitronectin receptor antagonists
GB9815803D0 (en) Vitronectin receptor antagonists
GB9811295D0 (en) Vitronectin receptor antagonists